Jump Financial’s Corvus Pharmaceuticals CRVS Stock Holding History

Jump Financial’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.68M	Buy	313,400 +165,550	+112%	+$2.3M	0.04%	548
2026 Q1	$2.16M	Buy	+147,850	New	+$2.36M	0.03%	622
2025 Q2	–	Sell	-45,013	Closed	-$143K	–	1866
2025 Q1	$143K	Buy	+45,013	New	+$212K	﹤0.01%	1479
2022 Q1	–	Sell	-55,500	Closed	-$134K	–	1605
2021 Q4	$134K	Buy	+55,500	New	+$215K	0.01%	1183

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Jump Financial's CRVS Position: Q2 2026 in Review

Jump Financial increased its Corvus Pharmaceuticals (CRVS) stake by 112% in Q2 2026, buying an estimated $2.3M and bringing the position to 313,400 shares worth $4.68M. The position accounts for 0.04% of the portfolio, ranked #548.

Jump Financial first reported a position in CRVS in Q4 2021 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Jump Financial held 313,400 shares of Corvus Pharmaceuticals worth $4.68M as of Q2 2026.
Jump Financial bought 165,550 Corvus Pharmaceuticals shares in Q2 2026, an estimated $2.3M.
Corvus Pharmaceuticals made up 0.04% of Jump Financial's portfolio in Q2 2026, its #548 holding.
Jump Financial first reported a position in Corvus Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.